109 related articles for article (PubMed ID: 33196013)
1. Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D; Ramazzotti D; Aroldi A; Redaelli S; Magistroni V; Pirola A; Niro A; Massimino L; Mastini C; Brambilla V; Bombelli S; Bungaro S; Morotti A; Rea D; Stagno F; Martino B; Campiotti L; Caocci G; Usala E; Merli M; Onida F; Bregni M; Elli EM; Fumagalli M; Ciceri F; Perego RA; Pagni F; Mologni L; Piazza R; Gambacorti-Passerini C
Hemasphere; 2020 Dec; 4(6):e497. PubMed ID: 33196013
[TBL] [Abstract][Full Text] [Related]
2. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
3. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract][Full Text] [Related]
4.
Iaquinta G; Scalzulli E; Angeloni S; Carmosino I; Costa A; Ielo C; Passucci M; Masucci C; Martelli M; Grammatico P; Breccia M
Leuk Lymphoma; 2023 Oct; 64(10):1730-1732. PubMed ID: 37435984
[TBL] [Abstract][Full Text] [Related]
5. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
Piazza R; Valletta S; Winkelmann N; Redaelli S; Spinelli R; Pirola A; Antolini L; Mologni L; Donadoni C; Papaemmanuil E; Schnittger S; Kim DW; Boultwood J; Rossi F; Gaipa G; De Martini GP; di Celle PF; Jang HG; Fantin V; Bignell GR; Magistroni V; Haferlach T; Pogliani EM; Campbell PJ; Chase AJ; Tapper WJ; Cross NC; Gambacorti-Passerini C
Nat Genet; 2013 Jan; 45(1):18-24. PubMed ID: 23222956
[TBL] [Abstract][Full Text] [Related]
6. Atypical Chronic Myelogenous Leukemia,
Diamantopoulos PT; Viniou NA
Front Oncol; 2021; 11():722507. PubMed ID: 34868917
[TBL] [Abstract][Full Text] [Related]
7. ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine.
Fontana D; Mauri M; Renso R; Docci M; Crespiatico I; Røst LM; Jang M; Niro A; D'Aliberti D; Massimino L; Bertagna M; Zambrotta G; Bossi M; Citterio S; Crescenzi B; Fanelli F; Cassina V; Corti R; Salerno D; Nardo L; Chinello C; Mantegazza F; Mecucci C; Magni F; Cavaletti G; Bruheim P; Rea D; Larsen S; Gambacorti-Passerini C; Piazza R
Nat Commun; 2020 Nov; 11(1):5938. PubMed ID: 33230096
[TBL] [Abstract][Full Text] [Related]
8. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N; Elli EM; Abruzzese E; Palumbo GA; Benevolo G; Tiribelli M; Bonifacio M; Tieghi A; Caocci G; D'Adda M; Bergamaschi M; Binotto G; Heidel FH; Cavazzini F; Crugnola M; Pugliese N; Bosi C; Isidori A; Bartoletti D; Auteri G; Latagliata R; Gandolfi L; Martino B; Scaffidi L; Cattaneo D; D'Amore F; Trawinska MM; Stella R; Markovic U; Catani L; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Vianelli N; Breccia M; Russo D; Cavo M; Iurlo A; Palandri F
Br J Haematol; 2021 Apr; 193(2):356-368. PubMed ID: 33222197
[TBL] [Abstract][Full Text] [Related]
9. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Gerds AT; Savona MR; Scott BL; Talpaz M; Egyed M; Harrison CN; Yacoub A; Vannucchi A; Mead AJ; Kiladjian JJ; O'Sullivan J; García-Gutiérrez V; Bose P; Rampal RK; Miller CB; Palmer J; Oh ST; Buckley SA; Mould DR; Ito K; Tyavanagimatt S; Smith JA; Roman-Torres K; Devineni S; Craig AR; Mascarenhas JO
Blood Adv; 2020 Nov; 4(22):5825-5835. PubMed ID: 33232476
[TBL] [Abstract][Full Text] [Related]
10. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
11. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.
Marcellino BK; Farnoud N; Cassinat B; Lu M; Verger E; McGovern E; Patel M; Medina-Martinez J; Levine MF; Arango Ossa JE; Zhou Y; Kosiorek H; Mehrotra M; Houldsworth J; Dueck A; Rossi M; Mascarenhas J; Kiladjian JJ; Rampal RK; Hoffman R
Blood Adv; 2020 Nov; 4(22):5735-5744. PubMed ID: 33216890
[TBL] [Abstract][Full Text] [Related]
12. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.
Nann D; Ramis-Zaldivar JE; Müller I; Gonzalez-Farre B; Schmidt J; Egan C; Salmeron-Villalobos J; Clot G; Mattern S; Otto F; Mankel B; Colomer D; Balagué O; Szablewski V; Lome-Maldonado C; Leoncini L; Dojcinov S; Chott A; Copie-Bergman C; Bonzheim I; Fend F; Jaffe ES; Campo E; Salaverria I; Quintanilla-Martinez L
Blood Adv; 2020 Nov; 4(22):5652-5665. PubMed ID: 33211828
[TBL] [Abstract][Full Text] [Related]
13. The New ELN Recommendations for Treating CML.
Hehlmann R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207600
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
15. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
[TBL] [Abstract][Full Text] [Related]
16. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved.
Shallis RM; Gale RP; Lazarus HM; Roberts KB; Xu ML; Seropian SE; Gore SD; Podoltsev NA
Blood Rev; 2021 May; 47():100773. PubMed ID: 33213985
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.
Dragani M; Rege Cambrin G; Berchialla P; Dogliotti I; Rosti G; Castagnetti F; Capodanno I; Martino B; Cerrano M; Ferrero D; Gambacorti-Passerini C; Crugnola M; Elena C; Breccia M; Iurlo A; Cattaneo D; Galimberti S; Gozzini A; Bocchia M; Lunghi F; Cedrone M; Sgherza N; Luciano L; Russo S; Santoro M; Giai V; Caocci G; Levato L; Abruzzese E; Sora F; Saglio G; Fava C
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33213044
[TBL] [Abstract][Full Text] [Related]
18. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Gupta V; Griesshammer M; Martino B; Foltz L; Tavares R; Al-Ali HK; Giraldo P; Guglielmelli P; Lomaia E; Bouard C; Paley C; Tiwari R; Zor E; Raanani P
Leuk Lymphoma; 2021 Apr; 62(4):918-926. PubMed ID: 33210570
[TBL] [Abstract][Full Text] [Related]
19. Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party.
Bazarbachi AH; Al Hamed R; Labopin M; Halaburda K; Labussiere H; Bernasconi P; Schroyens W; Gandemer V; Schaap NPM; Loschi M; Jindra P; Snowden J; Wu D; Guffroy B; Rovira M; Chantepie SP; Poiré X; Lopez-Corral L; Nikolousis M; Pelosini M; Ciceri F; Baron F; Bazarbachi A; Corbacioglu S; Savani BN; Peric Z; Nagler A; Carreras E; Mohty M
Bone Marrow Transplant; 2021 Apr; 56(4):917-927. PubMed ID: 33208915
[TBL] [Abstract][Full Text] [Related]
20. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
Jia R; Balligand T; Atamanyuk V; Nivarthi H; Xu E; Kutzner L; Weinzierl J; Nedelec A; Kubicek S; Lesyk R; Zagrijtschuk O; Constantinescu SN; Kralovics R
Blood; 2021 Apr; 137(14):1920-1931. PubMed ID: 33202418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
